MIRA Pharmaceuticals, Inc.

Quotes on MIRA Pharmaceuticals, a developer of treatments for neurological and neuropsychiatric disorders, <a href="https://finance.yahoo.com/quote/MIRA/">jumped</a> almost 20% yesterday, April 16, before giving back some of the gains in after-hours trading. The surge came after the company reported positive animal trial results of its drug candidate for diabetic neuropathy, a condition in which nerves are damaged due to high blood sugar levels.

MIRA Pharmaceuticals jumps 20% on successful trial of ketamine analog


Lisata Therapeutics, Inc.

Novo Nordisk A/S

Quotes on Lisata Therapeutics, a pharmaceutical company developing therapies to combat tumors, <a href="https://finance.yahoo.com/quote/LSTA/">gained</a> more than 10% yesterday, April 15, after it announced a partnership with one of the largest industry manufacturers, Catalent, to evaluate the efficacy of a promising Lisata therapy. Since December, Catalent has been owned by Novo Holdings, the controlling shareholder of Denmark’s Novo Nordisk, a global leader in weight-loss medications.

Biotech small cap Lisata Therapeutics jumps 10% on partnership with Novo subsidiary


Longeveron Inc.

Zacks Small-Cap Research (Zacks SCR) <a href="https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_03202025_LGVN_Sorensen.pdf">believes</a> that Longeveron, a micro-cap developer of cellular therapies for aging-related diseases, is worth more than five times its current share price. Its outlook has been bolstered after U.S. authorities gave the <a href="https://scr.zacks.com/news/news-details/2025/LGVN-Announces-Positive-Alzheimers-News/default.aspx">green light</a> to trials of the company’s Alzheimer’s drug and granted it a special designation. Overall, Alzheimer’s drugs are <a href="https://www.bloomberg.com/news/articles/2025-01-10/alzheimer-s-drugs-from-lilly-novo-and-roche-in-focus-for-investors?sref=Y0jVLcFo&amp;utm_source=in_materials#:~:text=Investors%20seeking%20the%20next%20obesity%2Dlike%20market%20opportunity%20will%20be%20closely%20watching%20developments%20related%20to%20treatments%20for%20Alzheimer%E2%80%99s%20disease%20in%202025.">seen</a> as a highly promising niche for investors.

Pharmaceutical Companies